About Dr. Zou Duowu
Dr. Zou Duowu (邹多武) is a Professor, Doctoral Supervisor, and one of China's leading gastroenterologists specializing in inflammatory bowel disease (IBD), based at the Department of Gastroenterology, Changhai Hospital, Naval Medical University (Second Military Medical University). With extensive clinical and research expertise in the diagnosis and management of Crohn's disease, ulcerative colitis, and related conditions, Dr. Zou is recognized as a senior authority in IBD medicine at one of China's most distinguished military academic medical centers and one of the highest-volume gastroenterology departments in Shanghai.
Inflammatory bowel disease — encompassing Crohn's disease and ulcerative colitis — is a chronic, relapsing immune-mediated condition of the gastrointestinal tract that affects millions of people worldwide and is increasing rapidly in incidence in China and across Asia. Its optimal management requires a level of specialist expertise that goes well beyond general gastroenterology: precise disease phenotyping using endoscopy, cross-sectional imaging, and histopathology; careful selection and monitoring of immunosuppressive and biological therapies; proactive management of disease complications including strictures, fistulas, abscesses, and dysplasia; and close coordination with colorectal surgery, nutrition support, and psychology for comprehensive, multidisciplinary care. Dr. Zou's clinical practice at Changhai Hospital — supported by the hospital's comprehensive endoscopy, imaging, and surgical programs — provides international patients with access to the full spectrum of modern IBD management, from induction and maintenance of remission through biological therapy optimization and surgical planning.
Hospital Affiliation: Department of Gastroenterology, Changhai Hospital
Changhai Hospital (长海医霂), affiliated with Naval Medical University, is one of Shanghai's largest and most prestigious academic medical centers and a national leader in gastroenterology and digestive endoscopy. Its Department of Gastroenterology manages one of the largest IBD caseloads in Shanghai, supported by a dedicated IBD clinic with structured follow-up, a multidisciplinary IBD team integrating gastroenterology, colorectal surgery, radiology, pathology, nutrition support, and psychology, and an active IBD research program participating in national and international clinical trials of novel biological and small molecule therapies.
The department's endoscopy program — one of the highest-volume in China — provides comprehensive endoscopic assessment of IBD disease activity and extent, including high-definition colonoscopy with chromoendoscopy for dysplasia surveillance, small bowel capsule endoscopy and device-assisted enteroscopy for small bowel Crohn's disease, and endoscopic balloon dilation for IBD-related strictures. Its cross-sectional imaging program provides MRI enterography and CT enterography for small bowel Crohn's disease assessment and fistula mapping, and pelvic MRI for perianal Crohn's disease characterization.
Clinical Specialties: What Dr. Zou Duowu Treats
- Crohn's disease — comprehensive disease phenotyping using the Montreal classification (location, behavior, perianal involvement); endoscopic and cross-sectional imaging assessment of disease activity and extent; induction of remission with corticosteroids, exclusive enteral nutrition (EEN), and biological therapy; maintenance of remission with azathioprine, 6-mercaptopurine, methotrexate, and biological agents; biological therapy selection and optimization including anti-TNF agents (infliximab, adalimumab), anti-integrin therapy (vedolizumab), anti-IL-12/23 therapy (ustekinumab), and JAK inhibitors (upadacitinib); therapeutic drug monitoring (TDM) for biological therapy optimization; management of Crohn's disease complications including strictures (endoscopic balloon dilation, surgical referral), fistulas (medical and surgical management), and abscesses (drainage and antibiotic therapy); perianal Crohn's disease management including seton placement coordination and anti-TNF therapy
- Ulcerative colitis — disease activity assessment using the Mayo score and endoscopic indices; induction of remission with 5-aminosalicylates (5-ASA), corticosteroids, and biological therapy for moderate-severe disease; maintenance of remission with 5-ASA, thiopurines, and biological agents; biological therapy for moderate-severe UC including infliximab, adalimumab, vedolizumab, ustekinumab, and ozanimod; JAK inhibitor therapy (tofacitinib, upadacitinib, filgotinib) for moderate-severe UC; management of acute severe ulcerative colitis (ASUC) including intravenous corticosteroids, infliximab rescue therapy, and cyclosporine; dysplasia surveillance colonoscopy with chromoendoscopy; coordination with colorectal surgery for proctocolectomy in refractory or dysplasia-associated UC
- Biological therapy optimization and therapeutic drug monitoring — systematic TDM of anti-TNF agents (infliximab, adalimumab) with trough level and anti-drug antibody measurement; proactive TDM-guided dose optimization to prevent loss of response; reactive TDM for secondary loss of response; switching strategies for primary non-response and secondary loss of response; biosimilar switching guidance
- IBD-related complications and extraintestinal manifestations — management of IBD-related anemia, nutritional deficiency, and malnutrition; assessment and management of extraintestinal manifestations including arthropathy, skin manifestations (erythema nodosum, pyoderma gangrenosum), ocular manifestations, and primary sclerosing cholangitis (PSC); bone density assessment and osteoporosis prevention in IBD; vaccination guidance for immunosuppressed IBD patients
- IBD in pregnancy — preconception counseling for IBD patients; management of IBD during pregnancy including safe medication selection; coordination with obstetrics for high-risk pregnancy monitoring; postpartum IBD management and breastfeeding guidance
- Microscopic colitis and other colitides — diagnosis and management of collagenous colitis and lymphocytic colitis; differentiation from IBD and other causes of chronic diarrhea; budesonide therapy and medication review
- Expert second opinion on IBD management — review of prior endoscopy, imaging, pathology, and treatment records for patients with IBD seeking a second opinion on diagnosis, disease activity assessment, biological therapy selection, or surgical indication; written English-language second opinion reports available through CMCS
Why International Patients Choose Dr. Zou Duowu and Changhai Hospital
International patients — particularly expatriates living in Shanghai and medical tourists from regions where IBD specialist expertise is limited or where access to biological therapies is restricted by cost or availability — seek consultation with Dr. Zou Duowu for reasons that reflect both the clinical depth of his IBD expertise and the practical advantages of accessing IBD care at Changhai Hospital.
For patients with Crohn's disease or ulcerative colitis that has not responded to standard therapies — or where biological therapy has been recommended but not yet initiated due to cost, access, or uncertainty about agent selection — Dr. Zou's systematic approach to disease phenotyping, biological therapy selection, and TDM-guided optimization provides a level of IBD management sophistication that is difficult to access outside specialized IBD centers. The availability of the full range of approved biological agents and JAK inhibitors at Changhai Hospital — including vedolizumab, ustekinumab, and upadacitinib at costs substantially below those in Western healthcare systems — makes optimal IBD therapy accessible to international patients who cannot afford these agents at home.
For patients with refractory IBD who have failed multiple biological agents, Dr. Zou's expertise in switching strategies, combination therapy, and the evaluation of surgical options provides a comprehensive reassessment of treatment options that may identify effective strategies not previously considered. The close integration of the IBD medical and surgical programs at Changhai Hospital — including the colorectal surgery team's expertise in laparoscopic proctocolectomy with IPAA for ulcerative colitis and in Crohn's disease surgery — enables seamless multidisciplinary management of complex IBD cases requiring both medical and surgical expertise.
What to Expect at Your Consultation
Consultations with Dr. Zou Duowu at Changhai Hospital arranged through CMCS begin with a comprehensive review of all prior IBD records — including colonoscopy and small bowel endoscopy reports and biopsy pathology, MRI enterography and CT enterography reports, pelvic MRI for perianal disease, prior biological therapy records including agent, dose, duration, response, and TDM results, current and prior immunosuppressive medications, relevant laboratory investigations (CRP, ESR, fecal calprotectin, CBC, liver function, renal function, thiopurine metabolite levels), and the patient's IBD history including disease duration, prior flares, hospitalizations, and surgeries. CMCS will arrange certified translation of all medical records and investigation results in advance of the consultation.
Dr. Zou will assess the IBD phenotype and current disease activity, evaluate the adequacy of prior and current therapy, outline the recommended management strategy — including biological therapy selection or optimization, TDM-guided dose adjustment, and surgical referral where indicated — with detailed rationale, and coordinate multidisciplinary input from colorectal surgery, nutrition support, and radiology where appropriate. A written English-language consultation summary is provided after every appointment, and CMCS will facilitate direct communication between Dr. Zou's team and the patient's home gastroenterologist for continuity of care planning.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides comprehensive end-to-end support for international patients seeking IBD consultation with Dr. Zou Duowu at Changhai Hospital. Our services include priority consultation scheduling, certified medical record and endoscopy report translation, coordination of colonoscopy, MRI enterography, and laboratory investigations, on-site interpretation throughout the consultation, biological therapy administration coordination and pharmacy support, and written English-language reporting of all findings and recommendations. CMCS will also facilitate direct communication between Dr. Zou's team and the patient's home gastroenterologist to ensure seamless continuity of care.
📧 contract@medicalsh.com | 💬 WeChat: gezhanglao | 🌐 medicalsh.com
0 comentarios